Feb 18, 2024
CAR T-cell therapy involves genetically modifying a patient's own T-cells to express a chimeric antigen receptor (CAR) that recognizes a specific protein (antigen) on cancer cells. These modified T-cells are then infused back into the patient's body to target and destroy cancer cells.
One of the advantages of CAR T-cell therapy is its specificity. The CARs are designed to target specific antigens found on cancer cells, sparing healthy cells from damage, thus reducing some of the side effects associated with traditional cancer treatments like chemotherapy.
CAR T-cell therapy has shown remarkable efficacy in treating certain types of blood cancers, such as certain types of leukemia and lymphoma. Patients who have not responded to conventional treatments or have relapsed after initial treatment may benefit from CAR T-cell therapy.
While CAR T-cell therapy offers promising results, it can also lead to side effects, including cytokine release syndrome (CRS) and neurotoxicity. CRS occurs when the infused T-cells become activated and release cytokines, causing symptoms ranging from fever and flu-like symptoms to more severe complications.
CAR T-cell therapy is a relatively new and complex treatment that can be expensive. Additionally, access to CAR T-cell therapy may be limited based on factors such as healthcare coverage and availability of specialized treatment centers capable of administering the therapy.